nach oben

Rechtsmedizin

Erschienen in:

01.08.2014 | CME Zertifizierte Fortbildung

„Legal highs“

Chemie, Pharmakologie, Toxikologie und forensische Bedeutung

verfasst von: Dr. rer. nat. C. Hess, A. Maas, B. Madea

Erschienen in: Rechtsmedizin | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Bei „legal highs“ handelt es sich um synthetische Verbindungen mit psychoaktiven Wirkungen, die sich in Bezug auf Struktur und Wirkungsweise oft nur geringfügig von den bekannten illegalen Drogen unterscheiden. Neben der Strukturklasse der Phenethylamine gehören verschiedene Tryptamin- und Piperazinderivate sowie synthetische Cannabinoide zu diesen neu auf dem Markt auftretenden Substanzen. Der Konsum von Legal highs ist mit erheblichen gesundheitlichen Risiken bis hin zum Tod verbunden. Der Nachweis der immer weiter modifizierten Substanzen stellt eine große Herausforderung für die forensische Toxikologie dar.

Schmidt MM, Sharma A, Schifano F, Feinmann C (2011) „Legal highs“ on the net-Evaluation of UK-based Websites, products and product information. Forensic Sci Int 206:92–97PubMedCrossRef

Musshoff F, Hottmann L, Hess C, Madea B (2013) „Legal highs“ from the German internet-“bath salt drugs“ on the rise. Arch Kriminol 232:91–103PubMed

EMCDDA-Europol. 2011 Annual Report on the implementation of Council Decision 2005/387/JHA. 2012

EMCDDA-European Drug Report. 2012. 2014

Baron M, Elie M, Elie L (2011) An analysis of legal highs: do they contain what it says on the tin? Drug Test Anal 3:576–581PubMedCrossRef

Davies S, Wood DM, Smith G et al (2010) Purchasing ‚legal highs‘ on the Internet-is there consistency in what you get? QJM 103:489–493PubMedCrossRef

EMCDDA-Europol. 2011 Annual Report on the implementation of Council Decision 2005/387/JHA. 2012. 2014

Cole MD, Lea C, Oxley N (2002) 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): a review of the public domain literature. Sci Justice 42:223–224PubMedCrossRef

Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM (2013) 2C or not 2C: phenethylamine designer drug review. J Med Toxicol 9:172–178PubMedCentralPubMedCrossRef

10.

Zuba D, Sekula K, Buczek A (2013) 25C-NBOMe-new potent hallucinogenic substance identified on the drug market. Forensic Sci Int 227:7–14PubMedCrossRef

11.

Cohen BM, Butler R (2011) BZP-party pills: a review of research on benzylpiperazine as a recreational drug. Int J Drug Policy 22:95–101PubMedCrossRef

12.

Elliott S, Smith C (2008) Investigation of the first deaths in the United Kingdom involving the detection and quantitation of the piperazines BZP and 3-TFMPP. J Anal Toxicol 32:172–177PubMedCrossRef

13.

Corkery JM, Elliott S, Schifano F et al (2012) 2-DPMP (desoxypipradrol, 2-benzhydrylpiperidine, 2-phenylmethylpiperidine) and D2PM (diphenyl-2-pyrrolidin-2-yl-methanol, diphenylprolinol): a preliminary review. Prog Neuropsychopharmacol Biol Psychiatry 39:253–258PubMedCrossRef

14.

Miotto K, Striebel J, Cho AK, Wang C (2013) Clinical and pharmacological aspects of bath salt use: a review of the literature and case reports. Drug Alcohol Depend 132:1–12PubMedCrossRef

15.

Shulgin A (2014) Pihkal. A chemical love story

16.

Felgate HE, Felgate PD, James RA et al (1998) Recent paramethoxyamphetamine deaths. J Anal Toxicol 22:169–172PubMedCrossRef

17.

Kraner JC, McCoy DJ, Evans MA et al (2001) Fatalities caused by the MDMA-related drug paramethoxyamphetamine (PMA). J Anal Toxicol 25:645–648PubMedCrossRef

18.

Zaitsu K, Katagi M, Kamata T et al (2008) Determination of a newly encountered designer drug „p-methoxyethylamphetamine“ and its metabolites in human urine and blood. Forensic Sci Int 177:77–84PubMedCrossRef

19.

Sacks J, Ray MJ, Williams S, Opatowsky MJ (2012) Fatal toxic leukoencephalopathy secondary to overdose of a new psychoactive designer drug 2C-E („Europa“). Proc (Bayl Univ Med Cent) 25:374–376

20.

Balikova M (2005) Nonfatal and fatal DOB (2,5-dimethoxy-4-bromoamphetamine) overdose. Forensic Sci Int 153:85–91PubMedCrossRef

21.

Uchiyama N, Miyazawa N, Kawamura M et al (2010) Analysis of newly distributed designer drugs detected in the products purchased in fiscal year 2008. Yakugaku Zasshi 130:263–270PubMedCrossRef

22.

Braden MR, Parrish JC, Naylor JC, Nichols DE (2006) Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol 70:1956–1964PubMedCrossRef

23.

Walterscheid JP, Phillips GT, Lopez AE et al (2014) Pathological findings in 2 cases of fatal 25I-NBOMe toxicity. Am J Forensic Med Pathol 35:20–25PubMedCrossRef

24.

Hill SL, Doris T, Gurung S et al (2013) Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series. Clin Toxicol (Phila) 51:487–492

25.

Rose SR, Poklis JL, Poklis A (2013) A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug. Clin Toxicol (Phila) 51:174–177

26.

Snyder SH, Richelson E (1968) Psychedelic drugs: steric factors that predict psychotropic activity. Proc Natl Acad Sci U S A 60:206–213PubMedCentralPubMedCrossRef

27.

European Monitoring Centre for Drugs and Drug Addiction (2004) Report on the risk assessment of TMA-2 in the framework of the joint action on new synthetic drugs. EMCDDA, Lisbon. http://www.emcdda.eu.int. 2014

28.

Rosner P, Quednow B, Girreser U, Junge T (2005) Isomeric fluoro-methoxy-phenylalkylamines: a new series of controlled-substance analogues (designer drugs). Forensic Sci Int 148:143–156PubMedCrossRef

29.

Marona-Lewicka D, Rhee GS, Sprague JE, Nichols DE (1995) Psychostimulant-like effects of p-fluoroamphetamine in the rat. Eur J Pharmacol 287:105–113PubMedCrossRef

30.

Cozzi NV, Sievert MK, Shulgin AT et al (1999) Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur J Pharmacol 381:63–69PubMedCrossRef

31.

Nagai F, Nonaka R, Satoh Hisashi KK (2007) The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 559:132–137PubMedCrossRef

32.

Adamowicz P, Tokarczyk B, Stanaszek R, Slopianka M (2013) Fatal mephedrone intoxication-a case report. J Anal Toxicol 37:37–42PubMedCrossRef

33.

Fauquet JP, Morel E, Demarty C, Rapin JR (1976) Role of central catecholamines in the psychostimulant activity of pyrovalerone. Arch Int Pharmacodyn Ther 224:325–337PubMed

34.

Servin A, Fauquet JP, Jacquot C, Rapin JR (1978) Effects of pyrovalerone on peripheral noradrenergic mechanisms. Biochem Pharmacol 27:1693–1694PubMedCrossRef

35.

Simmler LD, Buser TA, Donzelli M et al (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168:458–470PubMedCentralPubMedCrossRef

36.

Heimann H, Lukacs G (1965) Experimental psychological differentiation of the effect of 2 psychostimulants (F-1983 and amphetamine) in humans. Psychopharmacologia 8:79–90PubMedCrossRef

37.

Kesha K, Boggs CL, Ripple MG et al (2013) Methylenedioxypyrovalerone („bath salts“), related death: case report and review of the literature. J Forensic Sci 58:1654–1659PubMedCrossRef

38.

Sauer C, Hoffmann K, Schimmel U, Peters FT (2011) Acute poisoning involving the pyrrolidinophenone-type designer drug 4’-methyl-alpha-pyrrolidinohexanophenone (MPHP). Forensic Sci Int 208:e20–e25PubMedCrossRef

39.

Parker MA, Marona-Lewicka D, Lucaites VL et al (1998) A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor. J Med Chem 41:5148–5149PubMedCrossRef

40.

Wood DM, Looker JJ, Shaikh L et al (2009) Delayed onset of seizures and toxicity associated with recreational use of Bromo-dragonFLY. J Med Toxicol 5:226–229PubMedCentralPubMedCrossRef

41.

Boer D de, Egberts T, Maes RA (1999) Para-methylthioamphetamine, a new amphetamine designer drug of abuse. Pharm World Sci 21:47–48PubMedCrossRef

42.

Huang X, Marona-Lewicka D, Nichols DE (1992) p-methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent. Eur J Pharmacol 229:31–38PubMedCrossRef

43.

De Letter EA, Coopman VA, Cordonnier JA, Piette MH (2001) One fatal and seven non-fatal cases of 4-methylthioamphetamine (4-MTA) intoxication: clinico-pathological findings. Int J Legal Med 114:352–356CrossRef

44.

Elliott SP (2001) Analysis of 4-methylthioamphetamine in clinical specimens. Ann Clin Biochem 38:339–347PubMedCrossRef

45.

Bye C, Munro-Faure AD, Peck AW, Young PA (1973) A comparison of the effects of 1-benzylpiperazine and dexamphetamine on human performance tests. Eur J Clin Pharmacol 6:163–169PubMedCrossRef

46.

Hashimoto K, Maeda H, Hirai K, Goromaru T (1993) Drug effects on distribution of [3H]3,4-methylenedioxymethamphetamine in mice. Eur J Pharmacol 228:247–256PubMed

47.

Murphy DL, Lesch KP, Aulakh CS, Pigott TA (1991) Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans. Pharmacol Rev 43:527–552PubMed

48.

Gaillard YP, Cuquel AC, Boucher A et al (2013) A fatality following ingestion of the designer drug meta-chlorophenylpiperazine (mCPP) in an asthmatic – HPLC-MS/MS detection in biofluids and hair. J Forensic Sci 58:263–269PubMedCrossRef

49.

Lecompte Y, Evrard I, Arditti J (2006) Metachlorophenylpiperazine (mCPP): a new designer drug. Therapie 61:523–530PubMedCrossRef

50.

Kovaleva J, Devuyst E, De Paepe P, Verstraete A (2008) Acute chlorophenylpiperazine overdose: a case report and review of the literature. Ther Drug Monit 30:394–398PubMedCrossRef

51.

Tanaka E, Kamata T, Katagi M et al (2006) A fatal poisoning with 5-methoxy-N, N-diisopropyltryptamine, Foxy. Forensic Sci Int 163:152–154PubMedCrossRef

52.

Alatrash G, Majhail NS, Pile JC (2006) Rhabdomyolysis after ingestion of „foxy“, a hallucinogenic tryptamine derivative. Mayo Clin Proc 81:550–551PubMedCrossRef

53.

Corkery JM, Durkin E, Elliott S et al (2012) The recreational tryptamine 5-MeO-DALT (N, N-diallyl-5-methoxytryptamine): a brief review. Prog Neuropsychopharmacol Biol Psychiatry 39:259–262PubMedCrossRef

54.

Lidder S, Dargan P, Sexton M et al (2008) Cardiovascular toxicity associated with recreational use of diphenylprolinol (diphenyl-2-pyrrolidinemethanol [D2PM]). J Med Toxicol 4:167–169PubMedCentralPubMedCrossRef

55.

Wood DM, Puchnarewicz M, Johnston A, Dargan PI (2012) A case series of individuals with analytically confirmed acute diphenyl-2-pyrrolidinemethanol (D2PM) toxicity. Eur J Clin Pharmacol 68:349–353PubMedCrossRef

56.

Seetohul LN, Maskell PD, De Paoli G, Pounder DJ (2012) Deaths associated with new designer drug 5-IT. BMJ 345:e5625. DOI 10.1136/bmj.e5625PubMedCrossRef

57.

Seetohul LN, Pounder DJ (2013) Four fatalities involving 5-IT. J Anal Toxicol 37:447–451PubMedCrossRef

58.

Stellpflug SJ, Kealey SE, Hegarty CB, Janis GC (2014) 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): clinical case with unique confirmatory testing. J Med Toxicol 10:45–50PubMedCrossRef

59.

Gee P, Jerram T, Bowie D (2010) Multiorgan failure from 1-benzylpiperazine ingestion-legal high or lethal high? Clin Toxicol (Phila) 48:230–233

60.

Wood DM, Button J, Lidder S et al (2008) Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl) piperazine (TFMPP) and 1-benzylpiperzine (BZP). J Med Toxicol 4:254–257PubMedCentralPubMedCrossRef

61.

Boland DM, Andollo W, Hime GW, Hearn WL (2005) Fatality due to acute alpha-methyltryptamine intoxication. J Anal Toxicol 29:394–397PubMedCrossRef

62.

Vorce SP, Holler JM, Levine B, Past MR (2008) Detection of 1-benzylpiperazine and 1-(3-trifluoromethylphenyl)-piperazine in urine analysis specimens using GC-MS and LC-ESI-MS. J Anal Toxicol 32:444–450PubMedCrossRef

63.

Cody JT, Schwarzhoff R (1993) Interpretation of methamphetamine and amphetamine enantiomer data. J Anal Toxicol 17:321–326PubMedCrossRef

Titel: „Legal highs“
Chemie, Pharmakologie, Toxikologie und forensische Bedeutung
verfasst von: Dr. rer. nat. C. Hess
A. Maas
B. Madea
Publikationsdatum: 01.08.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Rechtsmedizin / Ausgabe 4/2014
Print ISSN: 0937-9819
Elektronische ISSN: 1434-5196
DOI: https://doi.org/10.1007/s00194-014-0964-3

Neu im Fachgebiet Rechtsmedizin

Open Access 15.04.2024 | Biomarker | Schwerpunkt: Next Generation Pathology

Springer Medizin

„Legal highs“

Chemie, Pharmakologie, Toxikologie und forensische Bedeutung

Zusammenfassung

Neu im Fachgebiet Rechtsmedizin

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Abstracts der 93. Jahrestagung der Deutschen Gesellschaft für Rechtsmedizin

Verbrennung nach letaler Intoxikation mit Doxylamin

Im Vorfeld der 4. Fortschreibung der Richtlinien zur Feststellung des Hirntods

Pflicht zur Offenbarung von Behandlungsfehlern nach dem Patientenrechtegesetz

Tödliche Verletzungen, verursacht durch eine Kuh

Untersuchungsstelle für Gewaltopfer am Institut für Rechtsmedizin der Universitätsmedizin Greifswald

Neu im Fachgebiet Rechtsmedizin

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie